ClinicalTrials.gov
public full text
Public Domain
Alpha Lipoic Acid and Diabetes Mellitus: Potential Effects on Peripheral Neuropathy
Patients with type 2 DM who are following will be enrolled into the study. Two visits were scheduled for data collection, physical examination and laboratory testing of the patients: the first prior to initiation of alpha lipoic acid (ALA) administration (baseline visit) and the second at the end of the third month following initiation of ALA (2nd visit).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy of Using Alpha-Lipoic Acid Supplement in Patients with Diabetic Neuropathy: A Meta-Analysis and Systematic Review#438776
- The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy#1338661
- Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients#826719
- Alpha Lipoic Acid for Treatment of Diabetic Neuropathy#121272
- A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy#915613
Record · ID 1364744
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive